PMID- 26620228 OWN - NLM STAT- MEDLINE DCOM- 20160607 LR - 20180923 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 470 IP - 1 DP - 2016 Jan 29 TI - LYATK1 potently inhibits LPS-mediated pro-inflammatory response. PG - 1-8 LID - S0006-291X(15)30959-1 [pii] LID - 10.1016/j.bbrc.2015.11.090 [doi] AB - Lipopolysaccharide (LPS)-primed monocytes/macrophages produce pro-inflammatory cytokines, which could lead to endotoxin shock. TGF-beta-activated kinase1 (TAK1) activation is involved in the process. In the current study, we studied the potential effect of a selective TAK1 inhibitor, LYTAK1, on LPS-stimulated response both in vitro and in vivo. We demonstrated that LYTAK1 inhibited LPS-induced mRNA expression and production of several pro-inflammatory cytokines [interleukin 1beta (IL-1beta), tumor necrosis factor-alpha (TNFalpha) and interleukin-6 (IL-6)] in RAW 264.7 macrophages. LYTAK1's activity was almost nullified with TAK1 shRNA-knockdown. Meanwhile, in both primary mouse bone marrow derived macrophages (BMDMs) and human peripheral blood mononuclear cells (PBMCs), LPS-induced pro-inflammatory cytokine production was again attenuated with LYTAK1 co-treatment. Molecularly, LYTAK1 dramatically inhibited LPS-induced TAK1-nuclear factor kappa B (NFkappaB) and mitogen-activated protein kinase (Erk, Jnk and p38) activation in RAW 264.7 cells, mouse BMDMs and human PBMCs. In vivo, oral administration of LYTAK1 inhibited LPS-induced activation of TAK1-NFkappaB-p38 in ex-vivo cultured PBMCs, and cytokine production and endotoxin shock in mice. Together, these results demonstrate that LYTAK1 inhibits LPS-induced production of several pro-inflammatory cytokines and endotoxin shock probably through blocking TAK1-regulated signalings. CI - Copyright (c) 2015 Elsevier Inc. All rights reserved. FAU - Xi, Feng AU - Xi F AD - Department of Intensive Care Unit, Taixing People(')s Hospital, Taixing, Jiangsu Province, 225400, China. FAU - Liu, Yuan AU - Liu Y AD - Department of Ophthalmology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. FAU - Wang, Xiujuan AU - Wang X AD - Department of Intensive Care Unit, Taixing People(')s Hospital, Taixing, Jiangsu Province, 225400, China. FAU - Kong, Wei AU - Kong W AD - Department of Intensive Care Unit, Taixing People(')s Hospital, Taixing, Jiangsu Province, 225400, China. FAU - Zhao, Feng AU - Zhao F AD - Department of Intensive Care Unit, Taixing People(')s Hospital, Taixing, Jiangsu Province, 225400, China. Electronic address: taixingzhaofeng163@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151124 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Cytokines) RN - 0 (Lipopolysaccharides) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.11.25 (MAP Kinase Kinase Kinases) RN - EC 2.7.11.25 (MAP kinase kinase kinase 7) SB - IM MH - Adult MH - Animals MH - Cytokines/*immunology MH - Dose-Response Relationship, Drug MH - Humans MH - Immunity, Cellular/drug effects/immunology MH - Leukocytes, Mononuclear/drug effects/*immunology MH - Lipopolysaccharides MH - MAP Kinase Kinase Kinases/*antagonists & inhibitors MH - Macrophages/drug effects/immunology MH - Mice MH - Mice, Inbred C57BL MH - Protein Kinase Inhibitors/*administration & dosage MH - RAW 264.7 Cells MH - Shock, Septic/chemically induced/*immunology/*prevention & control OTO - NOTNLM OT - LPS OT - LYTAK1 OT - Monocytes/macrophages and inflammation OT - TAK1 signalings EDAT- 2015/12/02 06:00 MHDA- 2016/06/09 06:00 CRDT- 2015/12/02 06:00 PHST- 2015/11/17 00:00 [received] PHST- 2015/11/20 00:00 [accepted] PHST- 2015/12/02 06:00 [entrez] PHST- 2015/12/02 06:00 [pubmed] PHST- 2016/06/09 06:00 [medline] AID - S0006-291X(15)30959-1 [pii] AID - 10.1016/j.bbrc.2015.11.090 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2016 Jan 29;470(1):1-8. doi: 10.1016/j.bbrc.2015.11.090. Epub 2015 Nov 24.